ClinicalTrials.gg
Enrolling by invitationNCT06447532INFLAMMATEUpdated Mar 12, 2025

Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammatory Markers in Breast Cancer Patients

An observational study in Breast Cancer, sponsored by Federal University of São Paulo. Enrolling by invitation at 13 sites in 8 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Federal University of São Paulo · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
4,500
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 351 studies in Breast Neoplasms with a site in Brazil — 52 open to participants now, 111 under way, 62 of them phase 3. Breast Neoplasms · Brazil.

Planned enrollment
3rd of 40
4,500 · median 251
Started
2024
with 15 others
Observational
40 of 351
3 open now
Primary completion
2024-12
later than 17 of 110 live
Registered
311th of 351
by date

Among the 351 studies in Breast Neoplasms with a site in Brazil, this one is the 3rd largest by planned enrollment of the 40 observational ones that give a count, is one of 16 that started in 2024, is one of 40 observational ones, reaches primary completion later than 17 of the 110 other live ones, and was the 311th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

52 of the 351 studies in Breast Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Breast Neoplasms with a site in Brazil, or all of them as a file.
02

Study summary

Breast cancer is the most common cancer in women globally, with 2.3 million new cases diagnosed in 2020. Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer is the most prevalent subtype, comprising 69% of all breast cancers in the USA. Within the tumor immune microenvironment, a higher intensity of myeloid cell infiltration and low levels of lymphocyte infiltration have been associated with worse outcomes. Markers in peripheral blood have emerged as predictive biomarkers that can be easily obtained non-invasively and at low cost. Experiments have confirmed the relative components of these tests (such as the immune cells) directly or indirectly participated in tumour occurrence, development, and immune escape, underscoring the potential use of laboratory tests as tumour biomarkers

Read the detailed description

In breast cancer, increased neutrophil levels and decreased lymphocyte levels in peripheral blood are associated with worse overall survival (OS). In HR+, HER2- metastatic breast cancers, low pretreatment NLR and high pretreatment absolute lymphocyte count (ALC) were related with better progression-free survival (PFS) and OS. The development of predictive models, based on machine learning (ML) algorithms it has been used in prognostication and assist in the diagnosis of different types of cancer.

Although regular laboratory tests have potential to be breast cancer biomarkers, a single test is yet to provide adequate sensitivity or specificity. Artificial intelligence (AI) could help with integrating data from multiple tests to aid diagnosis. Technical improvements such as data storage capacity, computing power, and better algorithms mean that ML can process clinically meaningful information from laboratory test data. Models' generalisability and stability still need to be confirmed, in view of limitations such as the absence of various pathological types, small cohorts, and lack of external validation. Therefore, a competitive model is also essential to achieve more accurate stratification of patients with breast cancer. The purpose of this retrospective multicentre study is to systematically evaluate the ability of laboratory tests to predict breast cancer, and develop a robust and generalisable model to assist in identifying patients with breast cancer.

03

Conditions studied

  • Breast Cancer

Keywords

  • breast cancer
  • machine learning
  • prognosis
  • inflammation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All the women involved in our study are patients who are diagnosed breast cancer pathologically and treated with surgery or neoadjuvant chemotherapy from January 1st 2013 to December 31st 2018.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women patients with age between 18 and 75 years old;
  • Invasive breast carcinoma patients diagnosed by pathology ;
  • Patients diagnosed between 1 January 2013 and 31 December 2018;
  • Have a complete blood count performed before the surgical intervention (mastectomy or conservative breast surgery) or chemotherapy;

Exclusion criteria

Exclusion Criteria:

Presence of hematological disorders;

  • Bilateral breast cancer;
  • Male;
  • Performance Status Score \< 70';
  • Inflammatory breast cancer and in situ carcinoma;
  • Pregnancy or breastfeeding;
  • Evidence of local or distant recurrence.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
4,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group I: Breast cancer

    All the participants involved in our study are women who are diagnosed breast cancer and treated with surgery or neoadjuvant chemotherapy from January 1st 2013 to December 31st 2018.

    Procedure: Surgery (Mastectomy or quadrantectomy)

Interventions

  • ProcedureSurgery (Mastectomy or quadrantectomy)

    Surgery (mastectomy or quadrantectomy); Neoadjuvant chemotherapy

    Also known as: Neoadjuvant chemotherapy

06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival

    Time frame: From the date of diagnosis to the date of death, assessed up to 120 months

Secondary outcomes

  1. Disease free survival

    Disease-free survival

    Time frame: From the date of diagnosis to the date of first progression (local recurrence of tumor or distant metastasis), assessed up to 60 months

07

Study locations

13 sites
  • Pablo Mandó
    Buenos Aires, Argentina
  • Rosekeila Simoes Nomeline
    Uberaba, Minas Gerais, Brazil
  • Tomás Reinert
    Porto Alegre, Rio Grande do Sul, Brazil
  • Idam Oliveira Junior
    Barretos, Sao Paulo, Brazil
  • César Cabello
    Campinas, Sao Paulo, Brazil
  • Daniel Guimaraes Tiezzi
    Ribeirão Preto, Sao Paulo, Brazil
  • Vasily Giannakeas
    Toronto, Ontario, Canada
  • Salma Elashwah
    Cairo, Egypt
  • Masahiro Takada
    Osaka, Japan
  • Masakazu Toi
    Tokyo, 113-8677, Japan
  • Wonshik Han
    Seul, Korea, Republic of
  • Cynthia Mayte Villarreal Garza
    Mexico City, Mexico
  • Cristina Saura
    Madrid, Spain
08

References and documents

Publications

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗
  • Faria SS, Giannarelli D, Cordeiro de Lima VC, Anwar SL, Casadei C, De Giorgi U, Madonna G, Ascierto PA, Mendoza Lopez RV, Chammas R, Capone M. Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics. Oncologist. 2024 Apr 4;29(4):e447-e454. doi: 10.1093/oncolo/oyad303. PubMed 37971409 ↗
  • Choi E, Bahadori MT, Schuetz A, Stewart WF, Sun J. Doctor AI: Predicting Clinical Events via Recurrent Neural Networks. JMLR Workshop Conf Proc. 2016 Aug;56:301-318. Epub 2016 Dec 10. PubMed 28286600 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Dec 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
Jun 7, 2024
StartActual
Aug 1, 2024
Primary completionActual
Dec 31, 2024
CompletionEst.
Feb 2027
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06447532
Collaborators
Kansai Medical University, University of Sao Paulo, Kyoto University, Barretos Cancer Hospital, Women's College Hospital, Emory University, University of Campinas, Brazil, Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno, Instituto Nacional de Cancer, Brazil, Universidade Federal do Triangulo Mineiro, Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud, Hospital Vall d'Hebron, Mansoura University, Seoul National University
Responsible party
Afonso Celso Pinto Nazario (Professor and Coordinator at the Department of Gynecology at EPM/UNIFESP., Federal University of São Paulo) — Principal investigator
First posted
Jun 7, 2024
Start date
Aug 1, 2024
Primary completion
Dec 31, 2024
Completion
Feb 2027 (estimated)
Last update
Mar 12, 2025

Study contacts

Afonso C Nazario, PhD
principal investigator · University Federal of Sao Paulo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion